{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T12:01:54Z","timestamp":1795089714574,"version":"4.10.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T00:00:00Z","timestamp":1691107200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81904133"],"award-info":[{"award-number":["81904133"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016305","name":"First Affiliated Hospital of Zhengzhou University","doi-asserted-by":"publisher","award":["2019QN28"],"award-info":[{"award-number":["2019QN28"]}],"id":[{"id":"10.13039\/501100016305","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202102080136"],"award-info":[{"award-number":["202102080136"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012248","name":"Collaborative Innovation Center for Modern Science and Technology and Industrial Development of Jiangxi Traditional Medicine","doi-asserted-by":"publisher","award":["2021XK18"],"award-info":[{"award-number":["2021XK18"]}],"id":[{"id":"10.13039\/501100012248","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Chin Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Myasthenia gravis (MG) is an antibody-mediated autoimmune disease and its pathogenesis is closely related to CD4\u2009+\u2009T cells. In recent years, gut microbiota is considered to play an important role in the pathogenesis of MG. Astragaloside IV (AS-IV) is one of the main active components extracted from Astragalus membranaceus and has immunomodulatory effects. To study the immunomodulatory effect of AS-IV and the changes of gut microbiota on experimental autoimmune myasthenia gravis (EAMG) mice, we explore the possible mechanism of AS-IV in improving MG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study, network pharmacology was utilized to screen the crucial targets of AS-IV in the treatment of MG. Subsequently, a Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis was performed to identify potential pathways through which AS-IV acts against MG. Furthermore, experimental investigations were conducted to validate the underlying mechanism of AS-IV in MG treatment. Before modeling, 5 mice were randomly selected as the control group (CFA group), and the other 10 were induced to EAMG model. These mice were randomly divided into EAMG group and EAMG\u2009+\u2009AS-IV group, n\u2009=\u20095\/group. In EAMG\u2009+\u2009AS-IV group, AS-IV was administered by gavage. CFA and EAMG groups were given the same volume of PBS. Body weight, grip strength and clinical symptoms were assessed and recorded weekly. At the last administration, the feces were collected for 16S RNA microbiota analysis. The levels of Treg, Th1 and Th17 cells in spleen and Th1 and Th17 cells in thymus were detected by flow cytometry. The levels of IFN-\u03b3, IL-17 and TGF-\u03b2 in serum were measured by ELISA. Furthermore, fecal microbial transplantation (FMT) experiments were performed for exploring the influence of changed intestinal flora on EAMG. After EAMG model was induced, the mice were treated with antibiotics daily for 4\u00a0weeks to germ-free. Then germ-free EAMG mice were randomly divided into two groups: FMT EAMG group, FMT AS-IV group, n\u2009=\u20093\/group. Fecal extractions from EAMG and EAMG\u2009+\u2009AS-IV groups as gathered above were used to administered daily to the respective groups for 4\u00a0weeks. Body weight, grip strength and clinical symptoms were assessed and recorded weekly. The levels of Treg, Th1 and Th17 cells in spleen and Th1 and Th17 cells in thymus were detected at the last administration. The levels of IFN-\u03b3, IL-17 and TGF-\u03b2 in serum were measured by ELISA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The network pharmacology and KEGG pathway analysis revealed that AS-IV regulates T cell pathways, including T cell receptor signaling pathway and Th17 cell differentiation, suggesting its potential in improving MG. Further experimental verification demonstrated that AS-IV administration improved muscle strength and body weight, reduced the level of Th1 and Th17 cells, enhanced the level of Treg cells, and resulted in alterations of the gut microbiota, including changes in beta diversity, the Firmicutes\/Bacteroidetes (F\/B) ratio, and the abundance of Clostridia in EAMG mice. We further conducted FMT tests and demonstrated that the EAMG Abx-treated mice which were transplanted the feces of mice treated with AS-IV significantly alleviated myasthenia symptoms, reduced Th1 and Th17 cells levels, and increased Treg cell levels.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study speculated that AS-IV ameliorates EAMG by regulating CD4\u2009+\u2009T cells and altering the structure and species of gut microbiota of EAMG.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13020-023-00798-6","type":"journal-article","created":{"date-parts":[[2023,8,4]],"date-time":"2023-08-04T21:01:36Z","timestamp":1691182896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Astragaloside IV ameliorates experimental autoimmune myasthenia gravis by regulating CD4\u2009+\u2009T cells and altering gut microbiota"],"prefix":"10.1186","volume":"18","author":[{"given":"Senhui","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linwen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingxing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuotai","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5367-0401","authenticated-orcid":false,"given":"Fengbin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,4]]},"reference":[{"issue":"1","key":"798_CR1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3233\/JND-140045","volume":"2","author":"J Deenen","year":"2015","unstructured":"Deenen J, Horlings C, Verschuuren J, Verbeek A, van Engelen B. The epidemiology of neuromuscular disorders: a comprehensive overview of the literature. J Neuromuscul Dis. 2015;2(1):73\u201385.","journal-title":"J Neuromuscul Dis"},{"key":"798_CR2","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","volume":"10","author":"A Carr","year":"2010","unstructured":"Carr A, Cardwell C, McCarron P, McConville J. A systematic review of population based epidemiological studies in Myasthenia Gravis. BMC Neurol. 2010;10:46.","journal-title":"BMC Neurol"},{"issue":"4","key":"798_CR3","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1007\/s00415-015-7963-5","volume":"263","author":"S Binks","year":"2016","unstructured":"Binks S, Vincent A, Palace J. Myasthenia gravis: a clinical-immunological update. J Neurol. 2016;263(4):826\u201334.","journal-title":"J Neurol"},{"issue":"10","key":"798_CR4","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/nri916","volume":"2","author":"A Vincent","year":"2002","unstructured":"Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol. 2002;2(10):797\u2013804.","journal-title":"Nat Rev Immunol"},{"key":"798_CR5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clim.2019.05.006","volume":"203","author":"J Song","year":"2019","unstructured":"Song J, Xi J, Yu W, Yan C, Luo S, Zhou L, et al. Inhibition of ROCK activity regulates the balance of Th1, Th17 and Treg cells in myasthenia gravis. Clin Immunol. 2019;203:142\u201353.","journal-title":"Clin Immunol"},{"issue":"4","key":"798_CR6","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1212\/WNL.44.4.728","volume":"44","author":"J Link","year":"1994","unstructured":"Link J, S\u00f6derstr\u00f6m M, Ljungdahl A, H\u00f6jeberg B, Olsson T, Xu Z, et al. Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis. Neurology. 1994;44(4):728\u201334.","journal-title":"Neurology"},{"issue":"1","key":"798_CR7","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-3083.2012.02703.x","volume":"76","author":"Z Wang","year":"2012","unstructured":"Wang Z, Wang W, Chen Y, Wei D. T helper type 17 cells expand in patients with myasthenia-associated thymoma. Scand J Immunol. 2012;76(1):54\u201361.","journal-title":"Scand J Immunol"},{"issue":"5","key":"798_CR8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s10875-012-9685-0","volume":"32","author":"W Xu","year":"2012","unstructured":"Xu W, Zhang A, Ren M, Zhang X, Wang F, Xu X, et al. Changes of Treg-associated molecules on CD4+CD25 +Treg cells in myasthenia gravis and effects of immunosuppressants. J Clin Immunol. 2012;32(5):975\u201383.","journal-title":"J Clin Immunol"},{"key":"798_CR9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2010.03.016","volume":"225","author":"M Masuda","year":"2010","unstructured":"Masuda M, Matsumoto M, Tanaka S, Nakajima K, Yamada N, Ido N, et al. Clinical implication of peripheral CD4+CD25+ regulatory T cells and Th17 cells in myasthenia gravis patients. J Neuroimmunol. 2010;225:123\u201331.","journal-title":"J Neuroimmunol"},{"key":"798_CR10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cyto.2015.06.011","volume":"78","author":"Y Xie","year":"2016","unstructured":"Xie Y, Li H, Jiang B, Li Y, Kaminski H, Kusner L. Elevated plasma interleukin-17A in a subgroup of Myasthenia Gravis patients. Cytokine. 2016;78:44\u20136.","journal-title":"Cytokine"},{"issue":"1","key":"798_CR11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.25122\/jml-2020-0145","volume":"14","author":"A Bubuioc","year":"2021","unstructured":"Bubuioc A, Kudebayeva A, Turuspekova S, Lisnic V, Leone M. The epidemiology of myasthenia gravis. J Med Life. 2021;14(1):7\u201316.","journal-title":"J Med Life"},{"issue":"1","key":"798_CR12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1212\/WNL.59.1.92","volume":"59","author":"F Somnier","year":"2002","unstructured":"Somnier F, Engel P. The occurrence of anti-titin antibodies and thymomas: a population survey of MG 1970\u20131999. Neurology. 2002;59(1):92\u20138.","journal-title":"Neurology"},{"key":"798_CR13","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1093\/brain\/123.4.665","volume":"123","author":"B MacDonald","year":"2000","unstructured":"MacDonald B, Cockerell O, Sander J, Shorvon S. The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK. Brain. 2000;123:665\u201376.","journal-title":"Brain"},{"issue":"1","key":"798_CR14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00281-014-0455-3","volume":"37","author":"Y Furusawa","year":"2015","unstructured":"Furusawa Y, Obata Y, Hase K. Commensal microbiota regulates T cell fate decision in the gut. Seminars in immunopathology. 2015;37(1):17\u201325.","journal-title":"Seminars in immunopathology"},{"key":"798_CR15","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.3389\/fmicb.2018.02627","volume":"9","author":"D Qiu","year":"2018","unstructured":"Qiu D, Xia Z, Jiao X, Deng J, Zhang L, Li J. Altered Gut Microbiota in Myasthenia Gravis. Front Microbiol. 2018;9:2627.","journal-title":"Front Microbiol"},{"key":"798_CR16","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/bs.apha.2019.08.002","volume":"87","author":"J Zhang","year":"2020","unstructured":"Zhang J, Wu C, Gao L, Du G, Qin X. Astragaloside IV derived from Astragalus membranaceus: a research review on the pharmacological effects. Adv Pharmacol. 2020;87:89\u2013112.","journal-title":"Adv Pharmacol"},{"issue":"7","key":"798_CR17","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.imbio.2014.03.005","volume":"219","author":"X Huang","year":"2014","unstructured":"Huang X, Tang L, Wang F, Song G. Astragaloside IV attenuates allergic inflammation by regulation Th1\/Th2 cytokine and enhancement CD4(+)CD25(+)Foxp3 T cells in ovalbumin-induced asthma. Immunobiology. 2014;219(7):565\u201371.","journal-title":"Immunobiology"},{"key":"798_CR18","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.taap.2018.10.024","volume":"362","author":"L Yang","year":"2019","unstructured":"Yang L, Xing F, Han X, Li Q, Wu H, Shi H, et al. Astragaloside IV regulates differentiation and induces apoptosis of activated CD4 T cells in the pathogenesis of experimental autoimmune encephalomyelitis. Toxicol Appl Pharmacol. 2019;362:105\u201315.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"798_CR19","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.4049\/jimmunol.172.4.2697","volume":"172","author":"F Baggi","year":"2004","unstructured":"Baggi F, Annoni A, Ubiali F, Milani M, Longhi R, Scaioli W, et al. Breakdown of tolerance to a self-peptide of acetylcholine receptor alpha-subunit induces experimental myasthenia gravis in rats. J Immunol. 2004;172(4):2697\u2013703.","journal-title":"J Immunol"},{"key":"798_CR20","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12974-015-0334-4","volume":"12","author":"C Wang","year":"2015","unstructured":"Wang C, Li H, Zhang M, Li X, Yue L, Zhang P, et al. Caspase-1 inhibitor ameliorates experimental autoimmune myasthenia gravis by innate dendric cell IL-1-IL-17 pathway. J Neuroinflammation. 2015;12:118.","journal-title":"J Neuroinflammation"},{"issue":"3","key":"798_CR21","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/imm.12322","volume":"143","author":"X Yao","year":"2014","unstructured":"Yao X, Kong Q, Xie X, Wang J, Li N, Liu Y, et al. Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses. Immunology. 2014;143(3):396\u2013405.","journal-title":"Immunology"},{"issue":"1","key":"798_CR22","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12016-016-8558-3","volume":"52","author":"F Truffault","year":"2017","unstructured":"Truffault F, de Montpreville V, Eymard B, Sharshar T, Le Panse R, Berrih-Aknin S. Thymic germinal centers and corticosteroids in myasthenia gravis: an immunopathological study in 1035 cases and a critical review. Clin Rev Allergy Immunol. 2017;52(1):108\u201324.","journal-title":"Clin Rev Allergy Immunol"},{"key":"798_CR23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaut.2013.12.008","volume":"52","author":"K Vrolix","year":"2014","unstructured":"Vrolix K, Fraussen J, Losen M, Stevens J, Lazaridis K, Molenaar P, et al. Clonal heterogeneity of thymic B cells from early-onset myasthenia gravis patients with antibodies against the acetylcholine receptor. J Autoimmun. 2014;52:101\u201312.","journal-title":"J Autoimmun"},{"issue":"11","key":"798_CR24","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1172\/JCI29894","volume":"116","author":"B Conti-Fine","year":"2006","unstructured":"Conti-Fine B, Milani M, Kaminski H. Myasthenia gravis: past, present, and future. J Clin Investig. 2006;116(11):2843\u201354.","journal-title":"J Clin Investig"},{"key":"798_CR25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1405.042","volume":"1132","author":"B Conti-Fine","year":"2008","unstructured":"Conti-Fine B, Milani M, Wang W. CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis. Ann N Y Acad Sci. 2008;1132:193\u2013209.","journal-title":"Ann N Y Acad Sci"},{"issue":"6603","key":"798_CR26","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/383787a0","volume":"383","author":"A Abbas","year":"1996","unstructured":"Abbas A, Murphy K, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383(6603):787\u201393.","journal-title":"Nature"},{"key":"798_CR27","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cyto.2017.05.008","volume":"96","author":"G Aguilo-Seara","year":"2017","unstructured":"Aguilo-Seara G, Xie Y, Sheehan J, Kusner L, Kaminski H. Ablation of IL-17 expression moderates experimental autoimmune myasthenia gravis disease severity. Cytokine. 2017;96:279\u201385.","journal-title":"Cytokine"},{"issue":"2","key":"798_CR28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mus.22070","volume":"44","author":"J Roche","year":"2011","unstructured":"Roche J, Capablo J, Larrad L, Gervas-Arruga J, Ara J, S\u00e1nchez A, et al. Increased serum interleukin-17 levels in patients with myasthenia gravis. Muscle Nerve. 2011;44(2):278\u201380.","journal-title":"Muscle Nerve"},{"key":"798_CR29","volume":"12","author":"P Chen","year":"2021","unstructured":"Chen P, Tang X. Gut microbiota as regulators of Th17\/Treg balance in patients with myasthenia gravis. Front Immunol. 2021;12: 803101.","journal-title":"Front Immunol"},{"issue":"3","key":"798_CR30","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/cei.12804","volume":"185","author":"A Rodr\u00edguez-Perea","year":"2016","unstructured":"Rodr\u00edguez-Perea A, Arcia E, Rueda C, Velilla P. Phenotypical characterization of regulatory T cells in humans and rodents. Clin Exp Immunol. 2016;185(3):281\u201391.","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"798_CR31","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.4049\/jimmunol.175.12.7898","volume":"175","author":"R Liu","year":"2005","unstructured":"Liu R, La Cava A, Bai X, Jee Y, Price M, Campagnolo D, et al. Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia. J Immunol. 2005;175(12):7898\u2013904.","journal-title":"J Immunol"},{"issue":"2","key":"798_CR32","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-11-3900","volume":"105","author":"A Balandina","year":"2005","unstructured":"Balandina A, L\u00e9cart S, Dartevelle P, Saoudi A, Berrih-Aknin S. Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. Blood. 2005;105(2):735\u201341.","journal-title":"Blood"},{"issue":"3","key":"798_CR33","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.clim.2012.09.012","volume":"145","author":"M Thiruppathi","year":"2012","unstructured":"Thiruppathi M, Rowin J, Ganesh B, Sheng J, Prabhakar B, Meriggioli M. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low\/-) T cells in patients with myasthenia gravis. Clin Immunol (Orlando, Fla). 2012;145(3):209\u201323.","journal-title":"Clin Immunol (Orlando, Fla)"},{"key":"798_CR34","volume":"80","author":"Y Hu","year":"2020","unstructured":"Hu Y, Wang J, Rao J, Xu X, Cheng Y, Yan L, et al. Comparison of peripheral blood B cell subset ratios and B cell-related cytokine levels between ocular and generalized myasthenia gravis. Int Immunopharmacol. 2020;80: 106130.","journal-title":"Int Immunopharmacol"},{"issue":"18","key":"798_CR35","doi-asserted-by":"crossref","first-page":"1901441","DOI":"10.1002\/advs.201901441","volume":"6","author":"P Zheng","year":"2019","unstructured":"Zheng P, Li Y, Wu J, Zhang H, Huang Y, Tan X, et al. Perturbed microbial ecology in myasthenia gravis: evidence from the gut microbiome and fecal metabolome. Adv Sci. 2019;6(18):1901441.","journal-title":"Adv Sci"},{"issue":"1","key":"798_CR36","doi-asserted-by":"crossref","first-page":"14384","DOI":"10.1038\/s41598-018-32700-y","volume":"8","author":"G Moris","year":"2018","unstructured":"Moris G, Arboleya S, Mancabelli L, Milani C, Ventura M, de Los R-G, et al. Fecal microbiota profile in a group of myasthenia gravis patients. Sci Rep. 2018;8(1):14384.","journal-title":"Sci Rep"},{"issue":"4","key":"798_CR37","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00535-010-0368-4","volume":"46","author":"A Andoh","year":"2011","unstructured":"Andoh A, Imaeda H, Aomatsu T, Inatomi O, Bamba S, Sasaki M, et al. Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn\u2019s disease using terminal restriction fragment length polymorphism analysis. J Gastroenterol. 2011;46(4):479\u201386.","journal-title":"J Gastroenterol"},{"issue":"5","key":"798_CR38","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.smim.2013.10.002","volume":"25","author":"K Kuhn","year":"2013","unstructured":"Kuhn K, Stappenbeck T. Peripheral education of the immune system by the colonic microbiota. Semin Immunol. 2013;25(5):364\u20139.","journal-title":"Semin Immunol"},{"issue":"46","key":"798_CR39","doi-asserted-by":"crossref","first-page":"19256","DOI":"10.1073\/pnas.0812681106","volume":"106","author":"Y Cong","year":"2009","unstructured":"Cong Y, Feng T, Fujihashi K, Schoeb T, Elson C. A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci USA. 2009;106(46):19256\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"798_CR40","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.cell.2017.09.022","volume":"171","author":"R Hebbandi Nanjundappa","year":"2017","unstructured":"Hebbandi Nanjundappa R, Ronchi F, Wang J, Clemente-Casares X, Yamanouchi J, Sokke Umeshappa C, et al. A gut microbial mimic that hijacks diabetogenic autoreactivity to suppress colitis. Cell. 2017;171(3):655-67.e17.","journal-title":"Cell"},{"issue":"1","key":"798_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2020.1848158","volume":"13","author":"H Zafar","year":"2021","unstructured":"Zafar H, Saier M. BacteroidesGut species in health and disease. Gut microbes. 2021;13(1):1\u201320.","journal-title":"Gut microbes"},{"issue":"7","key":"798_CR42","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.tim.2016.02.015","volume":"24","author":"T Konikoff","year":"2016","unstructured":"Konikoff T, Gophna U. Oscillospira: a central, enigmatic component of the human gut microbiota. Trends Microbiol. 2016;24(7):523\u20134.","journal-title":"Trends Microbiol"},{"key":"798_CR43","volume":"150","author":"N Xu","year":"2021","unstructured":"Xu N, Bai X, Cao X, Yue W, Jiang W, Yu Z. Changes in intestinal microbiota and correlation with TLRs in ulcerative colitis in the coastal area of northern China. Microb Pathog. 2021;150: 104707.","journal-title":"Microb Pathog"},{"issue":"32","key":"798_CR44","doi-asserted-by":"crossref","first-page":"22269","DOI":"10.18632\/oncotarget.25170","volume":"9","author":"A Consonni","year":"2018","unstructured":"Consonni A, Cordiglieri C, Rinaldi E, Marolda R, Ravanelli I, Guidesi E, et al. Administration of bifidobacterium and lactobacillus strains modulates experimental myasthenia gravis and experimental encephalomyelitis in Lewis rats. Oncotarget. 2018;9(32):22269\u201387.","journal-title":"Oncotarget"}],"container-title":["Chinese Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-023-00798-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13020-023-00798-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13020-023-00798-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T22:19:13Z","timestamp":1700518753000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmjournal.biomedcentral.com\/articles\/10.1186\/s13020-023-00798-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,4]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["798"],"URL":"https:\/\/doi.org\/10.1186\/s13020-023-00798-6","relation":{},"ISSN":["1749-8546"],"issn-type":[{"value":"1749-8546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,4]]},"assertion":[{"value":"18 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All in vivo experiments were performed in accordance with protocols approved by the Institutional Animal Ethics Committee of the First Affiliated Hospital of Guangzhou University of Chinese Medicine (Ethics No. TCMF1-2021012).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}